Skip to content

Clinical efficacy and mechanism of acupressure intervention for deficiency moderate-to-severe allergic rhinitis

Clinical efficacy and mechanism of acupressure intervention for deficiency moderate-to-severe allergic rhinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072292
Enrollment
Unknown
Registered
2023-06-08
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

the treatment group:Health education and the ARAT and the Mometasone furoate nasal spray
the control group 1:Health education and the non-specific acupoints acupressure and the Mometasone furoate nasal spray
the control group 2:Health education and the Mometasone furoate nasal spray

Sponsors

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1 Each participant must have a diagnosis of PAR according to the diagnostic criteria(3, 8, 9). 2 Aged 18 to 65. No gender limited. 3 Serum-specific IgE test positive for at least one or more of the following allergens: dust mites, house dust, animal fur dander, cockroaches or moulds. 4 Volunteered to participate in the trial and signed an informed consent form. 5 Ability of finishing the case report forms (CRF) by themselves or with the investigators assistance when necessary.

Exclusion criteria

Exclusion criteria: 1 Acute rhinitis (typhoid), vasomotor rhinitis, autonomic rhinitis, eosinophilic non-allergic rhinitis, or serum IgE negative. 2 Local skin lesions on the head and face such as burns, eczema, ulcers, frostbite breakouts. 3 Pregnancy or menstruation (After menstruation can be treated, the dating should be marked). Lactating women. 4 Participants with dysnoesia or behavioral disorders will be unable to cooperate with the study. 5 Participants who are easily lost to follow-up. 6 Those who are using systemic or local hormones for asthma or other diseases. 7 Participants with a history of asthma and currently treated with hormonal drugs. 8 Participants with allergies or contraindications to study drugs.

Design outcomes

Primary

MeasureTime frame
total nasal symptom score (TNSS);

Secondary

MeasureTime frame
Rhinoconjunctivitis Quality of Life Questionnaire-standardized score (RQLQs);rhinomanometry;acoustic rhinometry;adverse events (AE);relief medication scores;

Countries

China

Contacts

Public ContactKai Li

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

gdlikai@163.com+86 158 7654 7542

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026